Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $30.27, for a total value of $6,054,000.00.
• On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $29.59, for a total value of $5,918,000.00.

Roivant Sciences Trading Up 0.1%

ROIV traded up $0.05 on Friday, hitting $34.07. 12,406,494 shares of the company were exchanged, compared to its average volume of 6,151,323. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $34.68. The company has a market cap of $24.51 billion, a price-to-earnings ratio of -56.78 and a beta of 1.13. The firm has a 50-day moving average price of $29.57 and a two-hundred day moving average price of $26.72.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter in the prior year, the business earned ($0.29) EPS. Equities analysts expect that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. SBI Securities Co. Ltd. lifted its position in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares during the last quarter. Allworth Financial LP grew its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth about $47,000. Parallel Advisors LLC increased its position in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its holdings in shares of Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after purchasing an additional 2,665 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ROIV. Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. TD Cowen boosted their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Sanford C. Bernstein started coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective on the stock. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.